# Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

> **NCT06463028** · PHASE2 · RECRUITING · sponsor: **Faeth Therapeutics** · enrollment: 40 (estimated)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Sapanisertib
- **DRUG:** Serabelisib
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT06463028
- **Lead sponsor:** Faeth Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-12
- **Primary completion:** 2028-09
- **Final completion:** 2029-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06463028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06463028, "Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06463028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*